Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection

Frederik A. Verburg; Erik de Blois; Stijn Koolen; Mark W. Konijnenberg

doi:10.1186/s40658-023-00589-w

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection

Frederik A. Verburg^*
, Erik de Blois
, Stijn Koolen
, Mark W. Konijnenberg

^*Corresponding author for this work

Radboud University Medical Center

Research output: Contribution to journal › Article › Academic › peer-review

25 Citations (Scopus)

100 Downloads (Pure)

Abstract

Aim:

To explore the dosimetric effect of substituting Lu-177 with Tb-161 in targeted radionuclide therapy (TRT) using the registered tracers DOTA-TATE and PSMA-617.

Methods:

Using established kinetic data for [¹⁷⁷Lu]Lu-DOTA-TATE and [¹⁷⁷Lu]Lu-PSMA-617, radiation absorbed doses to typical tumour lesion as well as non-target tissues ([¹⁷⁷Lu]Lu-DOTA-TATE: kidneys, spleen and liver, [¹⁷⁷Lu]Lu-PSMA-617: kidneys, liver and salivary glands) were calculated for Lu-177 and Tb-161.

Results:

For both DOTA-TATE and PSMA-617, the substitution of Lu-177 with Tb-161 results in an increase in the delivered dose per unit of activity to tumour tissue by 40%. If an equivalent non-target delivered dose is strived for in order not to increase toxicity, based on kidney absorbed dose, 7400 MBq Lu-177 per cycle should be substituted with 5400 MBq Tb-161 for DOTA-TATE and 5300 MBq of Tb-161 for PSMA-617.

Conclusion:

When substituting Lu-177 with Tb-161, activity conversion is necessary in order not to exceed non-target dose limits.

Original language	English
Article number	69
Journal	EJNMMI Physics
Volume	10
Issue number	1
DOIs	https://doi.org/10.1186/s40658-023-00589-w
Publication status	Published - Dec 2023

Bibliographical note

Publisher Copyright:
© 2023, The Author(s).

Access to Document

10.1186/s40658-023-00589-wLicence: CC BY

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy potential dosimetric implications for activity selectionFinal published version, 1.11 MBLicence: CC BY

Cite this

@article{82a918df3bbc42fe8da6a5b1f0572e97,

title = "Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection",

abstract = "Aim: To explore the dosimetric effect of substituting Lu-177 with Tb-161 in targeted radionuclide therapy (TRT) using the registered tracers DOTA-TATE and PSMA-617. Methods: Using established kinetic data for [177Lu]Lu-DOTA-TATE and [177Lu]Lu-PSMA-617, radiation absorbed doses to typical tumour lesion as well as non-target tissues ([177Lu]Lu-DOTA-TATE: kidneys, spleen and liver, [177Lu]Lu-PSMA-617: kidneys, liver and salivary glands) were calculated for Lu-177 and Tb-161. Results: For both DOTA-TATE and PSMA-617, the substitution of Lu-177 with Tb-161 results in an increase in the delivered dose per unit of activity to tumour tissue by 40\%. If an equivalent non-target delivered dose is strived for in order not to increase toxicity, based on kidney absorbed dose, 7400 MBq Lu-177 per cycle should be substituted with 5400 MBq Tb-161 for DOTA-TATE and 5300 MBq of Tb-161 for PSMA-617.Conclusion: When substituting Lu-177 with Tb-161, activity conversion is necessary in order not to exceed non-target dose limits.",

author = "Verburg, \{Frederik A.\} and \{de Blois\}, Erik and Stijn Koolen and Konijnenberg, \{Mark W.\}",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = dec,

doi = "10.1186/s40658-023-00589-w",

language = "English",

volume = "10",

journal = "EJNMMI Physics",

issn = "2197-7364",

publisher = "Springer Science+Business Media",

number = "1",

}

TY - JOUR

T1 - Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy

T2 - potential dosimetric implications for activity selection

AU - Verburg, Frederik A.

AU - de Blois, Erik

AU - Koolen, Stijn

AU - Konijnenberg, Mark W.

PY - 2023/12

Y1 - 2023/12

N2 - Aim: To explore the dosimetric effect of substituting Lu-177 with Tb-161 in targeted radionuclide therapy (TRT) using the registered tracers DOTA-TATE and PSMA-617. Methods: Using established kinetic data for [177Lu]Lu-DOTA-TATE and [177Lu]Lu-PSMA-617, radiation absorbed doses to typical tumour lesion as well as non-target tissues ([177Lu]Lu-DOTA-TATE: kidneys, spleen and liver, [177Lu]Lu-PSMA-617: kidneys, liver and salivary glands) were calculated for Lu-177 and Tb-161. Results: For both DOTA-TATE and PSMA-617, the substitution of Lu-177 with Tb-161 results in an increase in the delivered dose per unit of activity to tumour tissue by 40%. If an equivalent non-target delivered dose is strived for in order not to increase toxicity, based on kidney absorbed dose, 7400 MBq Lu-177 per cycle should be substituted with 5400 MBq Tb-161 for DOTA-TATE and 5300 MBq of Tb-161 for PSMA-617.Conclusion: When substituting Lu-177 with Tb-161, activity conversion is necessary in order not to exceed non-target dose limits.

AB - Aim: To explore the dosimetric effect of substituting Lu-177 with Tb-161 in targeted radionuclide therapy (TRT) using the registered tracers DOTA-TATE and PSMA-617. Methods: Using established kinetic data for [177Lu]Lu-DOTA-TATE and [177Lu]Lu-PSMA-617, radiation absorbed doses to typical tumour lesion as well as non-target tissues ([177Lu]Lu-DOTA-TATE: kidneys, spleen and liver, [177Lu]Lu-PSMA-617: kidneys, liver and salivary glands) were calculated for Lu-177 and Tb-161. Results: For both DOTA-TATE and PSMA-617, the substitution of Lu-177 with Tb-161 results in an increase in the delivered dose per unit of activity to tumour tissue by 40%. If an equivalent non-target delivered dose is strived for in order not to increase toxicity, based on kidney absorbed dose, 7400 MBq Lu-177 per cycle should be substituted with 5400 MBq Tb-161 for DOTA-TATE and 5300 MBq of Tb-161 for PSMA-617.Conclusion: When substituting Lu-177 with Tb-161, activity conversion is necessary in order not to exceed non-target dose limits.

UR - https://www.scopus.com/pages/publications/85176210712

U2 - 10.1186/s40658-023-00589-w

DO - 10.1186/s40658-023-00589-w

M3 - Article

C2 - 37947917

AN - SCOPUS:85176210712

SN - 2197-7364

VL - 10

JO - EJNMMI Physics

JF - EJNMMI Physics

IS - 1

M1 - 69

ER -

Replacing Lu-177 with Tb-161 in DOTA-TATE and PSMA-617 therapy: potential dosimetric implications for activity selection

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this